We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$64.8B
1-Year Est. Return
42.7%
This Fund
S&P 500
This Quarter
Est. Return
+9.95%
1 Year Est. Return
+42.7%
3 Year Est. Return
+139.29%
5 Year Est. Return
+204.38%
10 Year Est. Return
+879.75%
AUM
$39.9B
AUM Growth
+$891M
(+2.3%)
Cap. Flow
-$1.96B
Cap. Flow
% of AUM
-4.91%
Top 10 Holdings %
Top 10 Hldgs %
26.01%
Holding
846
New
122
Increased
198
Reduced
391
Closed
98
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$171M |
| 2 |
Sensata Technologies
ST
|
+$145M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$133M |
| 4 |
Amazon
AMZN
|
+$67.2M |
| 5 |
AbbVie
ABBV
|
+$65.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Otis Worldwide
OTIS
|
+$164M |
| 2 |
Ross Stores
ROST
|
+$110M |
| 3 |
Bank of America
BAC
|
+$94.4M |
| 4 |
Freeport-McMoran
FCX
|
+$92.4M |
| 5 |
Five Below
FIVE
|
+$89.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.1% |
| 2 | Healthcare | 19.47% |
| 3 | Consumer Discretionary | 12.58% |
| 4 | Financials | 11.29% |
| 5 | Communication Services | 8.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KIN
576
DELISTED
Kindred Biosciences, Inc.
KIN
| $7.19M | 0.02% |
1,675,000
| – | – |
|
|
LTHM
577
DELISTED
Livent Corporation
LTHM
| $7.18M | 0.02% |
+800,000
| New | +$6.02M |
|
578
Outset Medical
OM
$86M
| $7M | 0.02% |
+9,333
| New | +$7.66M |
|
|
NVO
579
Novo Nordisk
NVO
$208B
| $6.94M | 0.02% |
200,000
-200,000
| -50% | -$6.67M |
|
580
Molson Coors Class B
TAP
$7.95B
| $6.9M | 0.02% |
205,636
-6,800
| -3% | -$245K |
|
581
Iron Mountain
IRM
$36.3B
| $6.88M | 0.02% |
256,952
-60,400
| -19% | -$1.72M |
|
582
CrowdStrike
CRWD
$220B
| $6.87M | 0.02% |
200,000
-300,000
| -60% | -$8.74M |
|
583
Regency Centers
REG
$14.1B
| $6.83M | 0.02% |
179,600
-5,700
| -3% | -$234K |
|
584
Huntington Bancshares
HBAN
$35.1B
| $6.83M | 0.02% |
744,300
+463,200
| +165% | +$4.31M |
|
|
DISCK
585
DELISTED
Discovery, Inc. Series C Common Stock
DISCK
| $6.78M | 0.02% |
345,909
-17,894
| -5% | -$353K |
|
586
Corpay
CPAY
$25.9B
| $6.72M | 0.02% |
28,208
-71,600
| -72% | -$17.7M |
|
587
COPT Defense Properties
CDP
$4.24B
| $6.67M | 0.02% |
281,167
+156,247
| +125% | +$3.9M |
|
|
WW
588
DELISTED
WW International
WW
| $6.61M | 0.02% |
+350,000
| New | +$8.24M |
|
589
argenx
ARGX
$55.4B
| $6.56M | 0.02% |
+25,000
| New | +$6.01M |
|
590
Broadridge
BR
$19B
| $6.56M | 0.02% |
49,700
-74,200
| -60% | -$9.92M |
|
591
SL Green Realty
SLG
$3.95B
| $6.49M | 0.02% |
144,643
+19,648
| +16% | +$911K |
|
592
Robert Half
RHI
$4.43B
| $6.47M | 0.02% |
122,200
-4,200
| -3% | -$224K |
|
593
Highwoods Properties
HIW
$3.51B
| $6.46M | 0.02% |
192,458
+115,617
| +150% | +$4.26M |
|
594
Mohawk Industries
MHK
$9.23B
| $6.45M | 0.02% |
+66,100
| New | +$5.94M |
|
595
Aclaris Therapeutics
ACRS
$860M
| $6.42M | 0.02% |
2,500,000
| – | – |
|
596
Huntington Ingalls Industries
HII
$12.7B
| $6.42M | 0.02% |
45,618
+6,012
| +15% | +$967K |
|
597
Ford
F
$55B
| $6.34M | 0.02% |
952,592
-421,108
| -31% | -$2.85M |
|
598
Albemarle
ALB
$14.9B
| $6.29M | 0.02% |
+70,479
| New | +$6.24M |
|
599
Tango Therapeutics
TNGX
$4.6B
| $6.22M | 0.02% |
+600,000
| New | +$6.13M |
|
600
Newell Brands
NWL
$2.53B
| $6.14M | 0.02% |
357,900
-63,700
| -15% | -$1.06M |
|
Similar funds
Adage Capital Partners's Q3 2020 Portfolio in Review
As of Q3 2020, Adage Capital Partners held 846 positions worth $39.9B, up 2.3% from $39.1B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Adage Capital Partners withdrew a net $1.96B in Q3 2020, closing 98 positions and reducing 391 holdings. Its most notable exit was Pfizer, an estimated $60.9M position sold in full.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 22% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Adage Capital Partners opened a new position in Bristol-Myers Squibb worth $134M.
- Adage Capital Partners's largest Q3 2020 buy was Bristol-Myers Squibb: 2,215,804 shares worth $134M.
- Adage Capital Partners added most to Johnson & Johnson in Q3 2020, an estimated $171M increase.
- Adage Capital Partners's biggest Q3 2020 reduction was Otis Worldwide, cutting an estimated $164M.
- Adage Capital Partners fully exited Pfizer in Q3 2020, selling an estimated $60.9M.
- Adage Capital Partners's ten largest holdings make up 26% of its $39.9B portfolio in Q3 2020.
- Adage Capital Partners opened 122 new positions and closed 98 in Q3 2020.
- Adage Capital Partners's portfolio value rose 2.3% quarter-over-quarter to $39.9B.
Based on Adage Capital Partners's 13F filing for Q3 2020, filed 16 Nov 2020.